Answers are grounded in this paper and cite their sources.
Low-grade gliomas are the most common brain tumour to occur in childhood. The identification of the mitogen-activated protein kinase pathway as the near-uniform driver of these tumours has led to the testing of therapies targeted at this pathway, with promising early results. The pan-RAF inhibitor tovorafenib is one of the most recent targeted agents to be tested for paediatric low-grade gliomas, with early data raising the prospect that we may be at the dawn of a new era in the management of this childhood brain tumour.
No takes yet. Share an insight, caveat, or question.
David S. Ziegler (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: